Table 3.
Clinical and radiological baseline measures.
| LD group n = 16 |
MD group n = 16 |
HD group n = 8 |
P-value | |
|---|---|---|---|---|
| Age, year | 52.6 ± 9.9 | 54.8 ± 12 | 57.7 ± 13.9 | .87 |
| Female, n (%) | 9 (56) | 9 (56) | 4 (50) | .94 |
| BMI (kg/m2) | 28.6 ± 3.8 | 26.1 ± 3.7 | 33 ± 4.9 | .78 |
| WOMAC, mean (SEM) | ||||
| Total | 36.9 ± 13.3 | 26.4 ± 14.8 | 38.6 ± 20 | .22 |
| A—pain | 8.3 ± 2.7 | 6.1 ± 2.1 | 8.3 ± 3.9 | .84 |
| B—Stifness | 3.1 ± 1.5 | 2.1 ± 1.7 | 3 ± 1.9 | 0.91 |
| C—Function | 25.5 ± 9.9 | 18.1 ± 12 | 27.2 ± 14.4 | 0.75 |
| Kellgren Lawrence (%) | ||||
| Grade II | 67% | 62% | 69% | 0.88 |
| Grade III | 33% | 38% | 31% | 0.91 |
| Knee MRI—WORMS | ||||
| Frequency of Involvement | ||||
| Cartilage | 94% | 92% | 91% | 0.97 |
| Osteophytes | 88% | 95% | 93% | 0.96 |
| Menisci | 74% | 69% | 72% | 0.94 |
| Score (mean, ±) | 47.8 ± 17.1 | 39.4 ± 12.2 | 44.3 ± 14.7 | 0.86 |
Data are presented as n (%) or mean ± SD. Abbreviations: 1LD, low-dose (2 × 106 UC-MSC); 2MD, medium-dose (20 × 106 UC-MSC); 3HD, high-dose (80 × 106 UC-MSC); 4BMI, body mass index; 5WOMAC, Western Ontario and Mc Master Universities Arthritis Index; 6 MRI, magnetic resonance imaging; 7 WORMS Whole-Organ Magnetic Resonance Imaging Score, 8SD, standard deviation.